Lupin Introduces Mirabegron ER Tablets in US Markets
Overview
Lupin Limited announced the launch of the United States Food and Drug Administration (FDA) approved mirabegron extended-release tablets, 25 mg in US markets.
Mirabegron Generic Counterpart
Mirabegron extended-release tablets, 25 mg is a generic equivalent of Myrbetriq extended-release tablets, 25 mg of Astellas Pharma Global Development, Inc.
Mirabegron: Annual sale
Mirabegron extended-release tablets, 25 mg had estimated annual sales of USD 1,019 million in the US (IQVIA MAT February 2024).
About Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!